SCHEMBL2915799

SCHEMBL2915799

CCOC(=O)C(=O)CC(=O)c1cccc(C)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
CYP1A2 P05177 2/20 0.50
GRM5 P41594 2/20 0.45
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 5/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
KDM4E B2RXH2 3/20 0.41
GAA P10253 1/20 0.41
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
TP53 P04637 2/20 0.40
LMNA P02545 1/20 0.40
PKM P14618 1/20 0.40
GPR35 Q9HC97 1/20 0.40
GBA1 P04062 1/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3943579 0.84 P2RX7 (0.54) P2RX7MEN1KMT2ACYP1A2GRM5
SCHEMBL2911150 0.84 CYP1A2 (0.46) MEN1KMT2ACYP1A2GRM5ALDH1A1
SCHEMBL8906409 0.81 ALDH1A1 (0.50) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL1065225 0.79 SMN1; SMN2 (0.49) CYP1A2ALDH1A1SMN1; SMN2POLBMAPT
SCHEMBL19806454 0.78 P2RX7 (0.57) P2RX7MEN1KMT2ACYP1A2GRM5
SCHEMBL109583 0.77 CYP1A2 (0.82) P2RX7MEN1KMT2ACYP1A2GRM5
SCHEMBL30693375 0.77 P2RX7 (0.59) P2RX7MEN1KMT2ACYP1A2GRM5
SCHEMBL5067835 0.77 P2RX7 (0.59) P2RX7MEN1KMT2ACYP1A2GRM5
SCHEMBL18974110 0.77 P2RX7 (0.56) P2RX7MEN1KMT2ACYP1A2GRM5
SCHEMBL13279457 0.76 ALDH1A1 (0.40) MEN1KMT2ACYP1A2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12325702-B2 ATF6 inhibitors and uses thereof ALTOS LABS, INC. (US) 2025-06-10 US disclosed
CN-119060036-A ATF6 inhibitors and uses thereof 阿尔托斯实验室公司 2024-12-03 CN disclosed
CN-112313224-B ATF6 inhibitors and uses thereof 阿尔托斯实验室公司 2024-08-13 CN disclosed
US-20240124434-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2024-04-18 US disclosed
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2021-07-22 US disclosed
EP-3774782-A2 ATF6 INHIBITORS AND USES THEREOF Black Belt TX Ltd (GB) 2021-02-17 EP disclosed
CN-112313224-A ATF6 inhibitors and uses thereof 黑带医疗有限责任公司 2021-02-02 CN disclosed
US-10829485-B2 ATF6 inhibitors and uses thereof BLACK BELT TX LTD (GB) 2020-11-10 US disclosed
US-10829485-B2 ATF6 inhibitors and uses thereof BLACK BELT TX LTD (GB) 2020-11-10 US disclosed
US-20190292179-A1 TGF Beta RECEPTOR ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2019-09-26 US disclosed
WO-2018017633-A1 TGF Beta RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-25 WO disclosed
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
CN-100436445-C Pyrazole derivative DAIICHI SEIYAKU CO (JP) 2008-11-26 CN disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
CN-1759110-A Pyrazole derivatives DAIICHI SEIYAKU CO (JP) 2006-04-12 CN disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124434-A1 ATF6 INHIBITORS AND USES THEREOF ATF4, XBP1, ATF1 P2RX7 3653/4885MEN1 4184/4885KMT2A 3989/4885
US-12325702-B2 ATF6 inhibitors and uses thereof ATF4, XBP1, ATF1 P2RX7 3653/4885MEN1 4184/4885KMT2A 3989/4885
US-20190292179-A1 TGF Beta RECEPTOR ANTAGONISTS TGFBR1, TGFBR2, TGFB1 P2RX7 1371/4885MEN1 2556/4885KMT2A 3067/4885
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 P2RX7 101/4885MEN1 4127/4885KMT2A 4370/4885
US-10829485-B2 ATF6 inhibitors and uses thereof ATF4, XBP1, ATF1 P2RX7 3653/4885MEN1 4184/4885KMT2A 3989/4885
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ATF4, XBP1, ATF1 P2RX7 3653/4885MEN1 4184/4885KMT2A 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.